+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management

Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management

Molecular Genetics and Metabolism 2019

Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP) are rare, genetic photodermatoses resulting from defects in enzymes of the heme-biosynthetic pathway. EPP results from the partial deficiency of ferrochelatase, and XLP results from gain-of-function mutations in erythroid specific ALAS2. Both disorders result in the accumulation of erythrocyte protoporphyrin, which is released in the plasma and taken up by the liver and vascular endothelium. The accumulated protoporphyrin is activated by sunlight exposure, generating singlet oxygen radical reactions leading to tissue damage and excruciating pain. About 2-5% of patients develop clinically significant liver dysfunction due to protoporphyrin deposition in bile and/or hepatocytes which can advance to cholestatic liver failure requiring transplantation. Clinically these patients present with acute, severe, non-blistering phototoxicity within minutes of sun-exposure. Anemia is seen in about 47% of patients and about 27% of patients will develop abnormal serum aminotransferases. The diagnosis of EPP and XLP is made by detection of markedly increased erythrocyte protoporphyrin levels with a predominance of metal-free protoporphyrin. Genetic testing by sequencing the FECH or ALAS2 gene confirms the diagnosis. Treatment is limited to sun-protection and there are no currently available FDA-approved therapies for these disorders. Afamelanotide, a synthetic analogue of α-melanocyte stimulating hormone was found to increase pain-free sun exposure and improve quality of life in adults with EPP. It has been approved for use in the European Union since 2014 and is not available in the U.S. In addition to the development of effective therapeutics, future studies are needed to establish the role of iron and the risks related to the development of hepatopathy in these patients.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 066446954

Download citation: RISBibTeXText

PMID: 30704898

DOI: 10.1016/j.ymgme.2019.01.020

Related references

Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria. JAMA Dermatology 153(8): 789-796, 2017

Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. Molecular Medicine 19: 26-35, 2013

Erythropoietic protoporphyria with porphyrinuria. Studies on the involvement of the liver in erythropoietic protoporphyria. Blut 22(4): 202-210, 1971

Unusual clinical manifestations of erythropoietic protoporphyria. Vestnik Dermatologii i Venerologii 48(7): 88-91, 1974

Erythropoietic protoporphyria : Clinical manifestations, diagnosis and new therapeutic possibilities. Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 67(3): 211-215, 2016

Mouse model for protoporphyria. III. Experimental production of chronic erythropoietic protoporphyria-like skin lesions. Journal of Investigative Dermatology 66(3): 188-195, 1976

Phototoxic histamine release induced by protoporphyria and uva light a possible role for mast cell activation in erythropoietic protoporphyria. Clinical Research 35(3): 686A, 1987

Erythropoietic protoporphyria: transfusion therapy and protoporphyria hepatits. British Journal of Dermatology 127(Supplement S40): 82-82, 1992

Comparative study of protoporphyrins in erythropoietic protoporphyria and griseofulvin-induced murine protoporphyria. Binding affinities, distribution, and fluorescence spectra in various blood fractions. Journal of Clinical Investigation 60(2): 380-389, 1977

Differential effect of protoporphyrin and uroporphyrin on mast cells correlation with clinical manifestations of erythropoietic protoporphyria and porphyria cutanea tarda. Clinical Researchpart 2: 662a, 1985

The molecular genetics of erythropoietic protoporphyria. Cellular and Molecular Biology 55(2): 118-126, 2013

Molecular genetics of erythropoietic protoporphyria. Photodermatology Photoimmunology & Photomedicine. 14(2): 70-73, Il, 1998

Molecular genetics of human ferrochelatase in erythropoietic protoporphyria. Clinical Science (London) 81(4): 5P, 1991

Genetics of heme synthetase deficiency in erythropoietic protoporphyria. Molecular Aspects of Medicine 11(1-2): 85-86, 1990

Anaesthetic management of erythropoietic protoporphyria. Paediatric Anaesthesia 10(5): 571, 2000